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Abstract
Background: Intense abdominal pain is the dominant feature of chronic pancreatitis. During the disease changes in central
pain processing, e.g. central sensitization manifest as spreading hyperalgesia, can result from ongoing nociceptive input.
The aim of the present study is to evaluate the effect of pregabalin on pain processing in chronic pancreatitis as assessed by
quantitative sensory testing (QST).
Methods: This randomized, double-blind, placebo-controlled trial evaluated effects of pregabalin on pain processing. QST
was used to quantify pain processing by measuring thresholds to painful electrical and pressure stimulation in six body
dermatomes. Descending endogenous pain modulation was quantified using the conditioned pain modulation (CPM)
paradigm to elicit a DNIC (diffuse noxious inhibitory controls) response. The main effect parameter was the change in the
sum of all body pain threshold values after three weeks of study treatment versus baseline values between both treatment
groups.
Results: 64 patients were analyzed. No differences in change in sum of pain thresholds were present for pregabalin vs.
placebo after three weeks of treatment. For individual dermatomes, change vs. baseline pain thresholds was significantly
greater in pregabalin vs. placebo patients for electric pain detection threshold in C5 (P = 0.005), electric pain tolerance
threshold in C5 (P = 0.04) and L1 (P = 0.05), and pressure pain tolerance threshold in T4 (P = 0.004). No differences were
observed between pregabalin and placebo regarding conditioned pain modulation.
Conclusion: Our study provides first evidence that pregabalin has moderate inhibitory effects on central sensitization
manifest as spreading hyperalgesia in chronic pancreatitis patients. These findings suggest that QST can be of clinical use
for monitoring pain treatments in the context of chronic pain.
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Introduction
The treatment of chronic pancreatitis patients can be a major
clinical challenge. [1] Achieving control of pain, one of the main
symptoms in this disease, can be difficult, and is often unsatisfac-
tory for patients and doctors. [2] An evidence based approach to
this pain for these patients does not exist, and to date there are no
uniformly accepted guidelines for treatment.
One of the main factors contributing to this problem is the lack
of evidence regarding the origin of chronic pancreatitis pain. [3]
Complications of pancreatic inflammation such as dilated
pancreatic duct, ductal stones and enlarged pancreatic head can
be treated endoscopically or surgically, but numerous patients
continue to suffer from pain despite technically successful
interventions. [4,5] Even bilateral splanchnicectomy, interrupting
ascending nociceptive pathways, fails in a substantial number of
patients. [6] In the last decade research has suggested that ongoing
nociceptive input from the pancreas is not the only explanation for
the debilitating abdominal pain in chronic pancreatitis. It is
increasingly accepted that changes in central pain processing, e.g.
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central sensitization or a shift towards pro-nociceptive pain
modulation, may result from chronic nociceptive input, manifest
as spreading hyperalgesia.[7–9] Ultimately, this process may
become entirely independent of nociceptive input and inhibitory
pain modulation, leading to an autonomous pain state. [10].
Medication targeting altered central pain processing, e.g.
gabapentinoids such as pregabalin, has been used successfully to
treat other chronic pain disorders such as post-herpetic neuralgia
and neuropathic pain of central origin.[11–13] In a recent
publication, we demonstrated that pregabalin has a significant
clinical analgesic effect in chronic pancreatitis patients. [14]
Quantitative sensory testing (QST) is a useful tool to quantify pain
processing in chronic pain patients, also in relation to the
effectiveness of analgesic interventions. [15,16] Apart from one
recent study on S-ketamine for chronic pancreatitis pain and one
using gabapentin for visceral pain in irritable bowel syndrome
[12,17], we are not aware of any studies having used QST to
describe the influence of centrally active medication on pain
processing in patients suffering from chronic pain disorders.
The aim of the present study is to evaluate the effect of
pregabalin as adjuvant pain treatment on pain processing,
measured by somatic QST, in patients with chronic pancreatitis.
We hypothesized that the hyperalgesia in chronic pancreatitis
patients with pain will undergo reduction under pregabalin
treatment, but not under placebo treatment.
Methods
Study Overview
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
This study was part of an investigator initiated double blind,
placebo-controlled, parallel-group study of increasing doses of
pregabalin conducted in the Netherlands (department of Surgery,
Radboud University Nijmegen Medical Center) and Denmark
(department of Gastroenterology & Hepatology, Aalborg Hospital,
Aarhus University Hospital). [14] The study was approved by the
responsible Ethical Committees in both countries (CMO region
Arnhem-Nijmegen, Nijmegen, The Netherlands and The local
Ethics Committee North Region, Aalborg, Denmark) and all
patients provided written informed consent. This article presents a
secondary and further analysis of the data obtained in a previous
trial [14] focusing primarily on experimental (QST) endpoints.
Patients
For trial inclusion, patients needed to have chronic abdominal
pain typical for pancreatitis (i.e. dull epigastric pain more than 3
days per week for at least 3 months) and a diagnosis of chronic
pancreatitis based on the Mayo Clinic diagnostic criteria. [18]
Another inclusion criterion was the use of a stable regime of
concomitant analgesic medication during the trial. Exclusion
criteria were: painful conditions other than chronic pancreatitis,
an abnormal electrocardiogram at screening visit, severe renal
impairment, active (or history of) major depression, hypersensitiv-
ity to pregabalin or any of it components and pregnant or lactating
patients. All patients that participated in this trial were included in
this study and analyzed in an intention to treat analysis.
Clinical endpoints i.e. pain scores and side-effects of the main
study are presented in more detail in the original manuscript. [14].
Healthy Controls
A control group was recruited in Denmark for comparison with
our chronic pancreatitis group to confirm the presence of
spreading hyperalgesia at the baseline pre-medication measure-
ment in the pancreatitis group. The controls were completely
healthy and had no history of a medical condition that could
interfere with our pain measurements.
Randomization and Treatment
Eligible patients at our outpatient departments were randomly
assigned in a one to one ratio to receive either pregabalin or
placebo. A pseudo-random code was computer generated for the
randomization blocks that had a size of six. Stratification of trial
participants was based on the absence or presence of diabetes
mellitus to minimize unbalance in distribution of undiagnosed
diabetic polyneuropathy. Patients received increasing doses of
either pregabalin or matching placebo for the study period of 3
weeks. Initial dose was 75 mg pregabalin twice a day (BID). After
three days this was increased to 150 mg pregabalin BID, with a
further increase to 300 mg BID after one week and for the rest of
the study period. An equivalent regime was followed in the
placebo arm. The same oral dosing schedule was prescribed to all
patients. Daily dosages were split into two equivalent doses, one
administered in the morning between 7 a.m. and 10 a.m. and one
in the evening between 7 p.m. and 10 p.m. In the case of
unacceptable side effects experienced by patients, a single
downward dose titration was allowed. Patients had to stay on
that final dosage for the remaining study period. Patients were
instructed to taper their study medication after three weeks of
treatment, by halving their dose for seven days, and then to stop
medication. Patients and those administrating study medication,
assessing outcomes, and analyzing data were blinded to group
assignment.
Study Visits
Patients considered for participation in this trial were screened
for eligibility and physical fitness. A systematic physical examina-
tion including a neurological examination was performed to assess
for any relevant conditions and neurological disorders. If eligible,
they were randomized by their treating physician for placebo or
pregabalin on their second visit, one week after their screening
visit. During their second visit all patients had a baseline QST
measurement, followed by another QST measurement at the end
of the study period of three weeks, i.e. before they were instructed
to taper their medication. During the whole study period patients
were instructed not to change their daily pain medication. They
were only allowed to take extra pain medication in the case of a
painful exacerbation of their chronic pancreatitis.
Quantitative Sensory Testing
QST took place using a standard temporal test sequence. [7]
Testing in females was not standardized with regard to phase of
the menstrual cycle because all female pancreatitis patients were
amenorrhoeic. Both the examiners (one in Denmark and one in
the Netherlands) were trained in and used the same QST protocol.
They performed the measurements in the same way and setting.
Pressure pain thresholds were based on two measurements and
electrical pain thresholds were based on three measurements.
After initial QST training per participating subject, pressure
pain thresholds were obtained for muscles overlying bone using a
pressure algometer with a 1.0 cm2 probe (Somedic Sales AB,
Horby, Sweden), at each of the following sites on the dominant
body side: clavicle (C5 dermatome), sternum (T4 dermatome),
pancreatic site (dorsal and ventral T10 dermatome), hip region (L1
dermatome) and knee (L4 dermatome) (Figure 1). The pancreas
and more distant dermatomes were chosen to observe segmental
and spreading hyperalgesia respectively. Two thresholds were
Pregabalin Effect on Sensitization in Pancreatitis
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measured: pressure pain detection threshold (pPDT) and pressure
pain tolerance threshold (pPTT). As the primary endpoint, the
sum of all the thresholds across dermatomes was calculated. [17].
Thresholds to electric constant current skin stimulation
(Digistim; Biometer A/S, Copenhagen, Denmark; tetanic stimu-
lation at 100 Hz, 0.2-ms square waves, self-adhesive electrodes
3 cm apart) were measured on the dominant side of the body at
the same sites as for pressure pain thresholds. Two thresholds were
measured: electric pain detection threshold (ePDT) and electric
pain tolerance threshold (ePTT). As the primary endpoint, the
sum of all the thresholds was again calculated. [17].
The conditioned pain modulation (CPM, previously known as
DNIC (diffuse noxious inhibitory control)) paradigm was per-
formed to test the ability of the patient to generate descending
inhibitory modulation. [19,20] Thus pressure pain thresholds
(pPTT, the test stimulus) were determined before and after the
cold pressor task (the conditioning stimulus), and the CPM effect
was determined as the relative change (%) in pressure pain
thresholds. For the cold pressor task the dominant hand was
immersed in ice-chilled water (1.0uC 60.3uC) continuously stirred
by a pump. The patient was told to remove the hand from the
water after two minutes of immersion - or sooner if the pain was
considered to be intolerable – and the immersion time noted.
Immediately after the cold pressor task, the subjects rated the pain
experienced during the test by use of a visual analogue scale for
quality control purposes. Pressure pain thresholds were obtained
in the non-dominant L4 dermatome (knee) immediately before
and after ice-water immersion.
Outcome Measures
The primary effect parameter for the study was the between
group difference (change) in sum of electric or pressure pain
thresholds after three weeks of study medication vs. baseline
values. [17] Between group differences in change in individual
dermatome thresholds and CPM paradigm results were secondary
endpoints.
Statistical Analysis
A pre hoc power calculation based on QST as an endpoint was
not performed because the study was a part of a randomized
clinical trial that investigated pregabalin, powered for a clinical
primary endpoint; i.e. change in clinical pain score.
For this mechanistic study we performed an intention to treat
analysis. We performed statistical analysis using the Statistica for
Windows Software Package (Release 7.0, Statsoft Inc, Tulsa, OK,
USA). All baseline characteristics and measurements are given as
medians with interquartile ranges. In view of the non-Gaussian
data distribution purely non-parametric analysis was performed.
Statistical significance was set at P#0.05.
The sum of all dermatomes for electric and pressure pain
detection and tolerance thresholds and the conditioned pain
modulation results were compared between the control and the
study group using Mann Whitney U testing to confirm spreading
hyperalgesia and pro-nociceptive pain modulation shift in the
pancreatitis patients. [14,17].
We calculated differences (change) in sum of thresholds or
individual thresholds between values at pre-medication baseline
and after three weeks’ medication. We then compared these
differences between the groups using Mann Whitney U testing.
Further analysis consisted of comparison of placebo vs. pregabalin
groups at pre-medication baseline and after three weeks’ treatment
for the sum of thresholds, for individual thresholds, or for
conditioned pain modulation values using Mann Whitney U
testing.
Results
Enrollment and Baseline Characteristics
From October 2008 to May 2010 a total of 236 patients
diagnosed with chronic pancreatitis in the last five years in one of
both hospitals were screened and 64 patients were randomized;
the study was completed without any incident. The majority of
patients not meeting inclusion criteria were free of pain, had
passed away or were no longer being treated in either of the
hospitals. 64 patients completed the study and were finally
analyzed in the intention to treat analysis (Figure 2). The number
of patients randomized to pregabalin or placebo treatment was
equally distributed between both hospitals. All patients (24 women,
40 men; median age 53 years (IQR (interquartile range) 45–62))
had pain due to chronic pancreatitis and were on a stable analgesic
therapy. Their median opioid consumption was 60 mg (IQR 11–
150) of morphine equivalents/day. Their median VAS score
before start of trial medication was 4 (IQR 2–5) at rest and 5 (IQR
4–7) during activity. Demographic data of the placebo and
pregabalin group are provided in Table 1. The healthy control
group consisted of 15 volunteers (7 women, 8 men; median age 38
years (IQR 35–49)). Only age was significantly different between
the healthy controls and chronic pancreatitis patients (P = 0.0001).
Baseline Measurements
Pancreatitis vs. healthy controls. The sum for pressure
and electric pain detection and tolerance thresholds of all
dermatomes was significantly lower for the pancreatitis group at
baseline vs. healthy controls (Table 2). At baseline chronic
pancreatitis patients tolerated the cold pressor task for 35 seconds
(IQR 24–70) and the healthy controls for 180 seconds (IQR 180–
180), (P = 0.000004). The healthy control group exhibited a
significantly greater CPM response than the pancreatitis patients
(P = 0.008) (Table 2). These results confirm hyperalgesia and a
shift to more pro-nociceptive pain modulation in our pancreatitis
patients.
Pregabalin vs. placebo patients. The sum of all derma-
tomes for pressure and electric pain detection and tolerance
thresholds at baseline was similar for the pregabalin vs. placebo
groups (Table 3). The same applied to the individual dermatomal
thresholds (Table 4).
At baseline, patients in the placebo group tolerated the cold
pressor task for 32 seconds (IQR 23–98) and in the pregabalin
group for 40 seconds (IQR 23–60), this was not statistically
different between groups. Also no significant difference was found
in baseline CPM response between the placebo and pregabalin
group (Table 4).
Effects of Treatment - Change in Measurements after
Three Weeks’ Study Medication
Electric pain thresholds. There was no significant differ-
ence in differences (change) in sums of electric pain detection and
tolerance thresholds between the groups (Table 5).
Figure 1. Dermatomes of measurement for quantitative sensory testing. Quantitative sensory testing was performed on the following sites
on the dominant body side (black dots): clavicle (C5 dermatome), sternum (T4 dermatome), pancreatic site (dorsal and ventral T10 dermatome), hip
region (L1 dermatome) and knee (L4 dermatome).
doi:10.1371/journal.pone.0042096.g001
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For individual electric pain detection thresholds, difference
(change) in dermatome C5 was significantly higher in the
pregabalin group (0.8 vs. 20.1; P= 0.005), with a trend for T10
(P = 0.055) (Table 5).
For individual electric pain tolerance thresholds, threshold
differences (change) for dermatome C5 (2.0 vs. 0.7; P= 0.04)
and L1 (1.9 vs. 20.2; P= 0.05) were significantly higher in the
pregabalin group (Table 5).
Pressure pain thresholds. There was no significant differ-
ence in differences (change) in sums of pressure pain detection and
tolerance thresholds between the groups (Table 5).
There was no significant difference in differences (change) in
individual dermatomal pressure pain detection thresholds between
the groups (Table 5).
For individual pressure pain tolerance thresholds, threshold
differences (change) for dermatome T4 (83 vs. 248; P= 0.004)
were significantly higher in the pregabalin group (Table 5).
CPM response. The difference (change) in cold pressor task
latency and CPM response was not significantly different between
the study groups (Table 5).
Effects of Treatment - Absolute Values after Three Weeks’
Study Medication
Electric pain thresholds. After 3 weeks’ study medication,
sum of all dermatomes for electric pain detection thresholds was
significantly higher in the pregabalin vs. placebo group (P= 0.01),
but not for electric pain tolerance thresholds (Table 3).
For individual dermatomes, electric pain detection thresholds
were significantly higher in the pregabalin group (T4; P = 0.04, L4;
P = 0.05 and T10BACK; P= 0.05) (Table 4). For individual
dermatomal electric pain tolerance thresholds, C5 (P= 0.05) and
L1 (P= 0.03) were significantly higher in the pregabalin group.
Pressure pain thresholds. Sums of – or individual dermatome
– pressure pain detection and tolerance thresholds were similar
between groups (Table 3 and 4) after three weeks’ study
medication.
CPM response. After three weeks of study medication
patients in the placebo group tolerated the cold pressor task for
42 seconds (IQR 21–116) and in the pregabalin group for 46
seconds (IQR 27–77); this was not statistically significant. Also no
significant difference could be found between groups for CPM
response after study medication (Table 4).
Discussion
Our study is the first to demonstrate that a three-week treatment
with pregabalin in chronic pancreatitis patients results in a
moderate antihyperalgesic effect compatible with a reduction of
central sensitization. A shift toward more anti-nociceptive pain
modulation appears less likely as mechanism due to the unaltered
conditioned pain modulation (CPM) response. Interestingly, this
early treatment effect is 1) visible only in dermatomes distant from
the referred pancreatic area, and 2) more pronounced for electric
skin thresholds than for pressure muscle thresholds. This implies 1)
better effects on distant as compared to segmental central
sensitization and 2) more effective hyperalgesia reduction in skin
compared to deeper tissues. These results suggest that measuring
pain sensitivity using quantitative sensory testing (QST) may prove
useful in monitoring the effects of pain treatment in chronic
pancreatitis and help us to diagnose and manage altered pain
processing in chronic pain disorders.
Nociceptive input from the pancreas spreads via ascending
pathways to spinal and supraspinal central nervous system
structures in chronic pancreatitis. [21,22] Ongoing nociceptive
Figure 2. Study enrollment and randomization. The majority of patients not meeting inclusion criteria had passed away, were free of pain or
were no longer being treated in either of the hospitals.
doi:10.1371/journal.pone.0042096.g002
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input increases neuronal excitability and synaptic strength, initially
at the spinal level, a state characterized by hyperalgesia near the
site of injury (segmental hyperalgesia). [3,23] With persisting
disease and nociception central sensitization spreads rostrally in
the central nervous system. [8] This progression is more marked
when descending inhibitory control mechanisms fail or in the
presence of descending facilitation, and may in due course result in
a widespread hyperalgesic state. [9] Ultimately, these central
changes may become independent of peripheral nociceptive input,
ending in an autonomous state. [6] Sensitization of the nervous
system is not specific for chronic pancreatitis, but is common
among other chronic pain disorders.[24–26] Congruently with the
described course of events, chronic pancreatitis patients in our
study did exhibit widespread hyperalgesia compared to healthy
controls.
The treatment of pain in chronic pancreatitis patients is usually
based on the WHO pain treatment ladder, which ends with opioid
treatment. Opioids can provide effective analgesia in some
pancreatitis patients, but may have considerable side effects or
even induce hyperalgesia. [27] Recently, pain treatments more
directly targeting the central nervous system, e.g. tricyclic
antidepressants or gabapentinoids, have been introduced to better
control disabling pain and hyperalgesia in chronic pain syn-
dromes. [28] Particularly the use of gabapentinoids has shown
clinical results in chronic pain disorders. [12,29,30] The clinical
analgesic effect of pregabalin in chronic pancreatitis patients was
recently published by our research group. [14] Two studies in an
Table 1. Demographic and clinical characteristics of patients.
Pregabalin (n=34) Placebo (n=30)
Age (years) 52 (46–58) 55 (42–65)
Males - no. (%) 20 (59) 19 (63)
Etiology - no. (%)
- Toxic-metabolic 16 (47) 17 (57)
- Idiopathic 11 (32) 11 (37)
- Genetic 2 (6) 0 (0)
- Autoimmune 1 (3) 0 (0)
- Recurrent and severe acute pancreatitis 2 (6) 1 (3)
- Obstructive 2 (6) 1 (3)
Diary pain score (visual analogue scale 0–10)
- Average pain 4 (2–6) 3 (2–5)
- Maximal pain 6 (4–8) 5 (4–7)
Concomitant analgesics - no. (%){
- None 3 (9) 2 (7)
- Weak analgesics 7 (21) 11 (37)
- Strong analgesics 24 (71) 17 (57)
MEQ/day 80 (10–158) 49 (13–128)
Duration of chronic pancreatitis (months) 92 (55–132) 83 (60–147)
Diabetes mellitus - no. (%) 10 (29) 10 (33)
Previous interventions for chronic pancreatitis – no. (%)
- Pancreas resection/drainage procedures 6 (18) 5 (17)
- Thoracoscopic splanchnic denervation 2 (6) 4 (13)
Patients treated with enzymes for pancreatic exocrine insufficiency - no. (%) 18 (53) 13 (43)
Ongoing alcohol abuse - no. (%){ 7 (21) 11 (37)
Current smoker - no. (%) 26 (76) 22 (77)
All values are medians with interquartile ranges unless mentioned otherwise. Percentages may not total 100 due to rounding.
{Weak analgesics were defined as NSAIDS, paracetamol, codeine and tramadol. Strong analgesics were defined as opioid based therapies.
{Alcohol abusing patients were defined as female patients drinking .14 units of alcohol per week or male patients drinking .21 units of alcohol per week.
‘MEQ’ is morphine equivalents, ‘pregabalin’ is pregabalin study group and ‘placebo’ is placebo study group.
No statistical differences between groups were observed.
doi:10.1371/journal.pone.0042096.t001
Table 2. Baseline data for conditioned pain modulation and
sum of pain thresholds for pancreatitis patients vs. healthy
controls.
Pancreatitis Control P-value
SUM ePDT (mA) 28 (21–41) 47 (21–65) 0.026
SUM ePTT (mA) 44 (34–62) 68 (48–92) 0.017
SUM pPDT (kPa) 1912 (951–2551) 2285 (2018–3018) 0.008
SUM pPTT (kPa) 2694 (2110–3185) 3234 (2785–4018) 0.005
CPM (%) 4.2 (0.0–22.4 ) 32.6 (10.4–41.8) 0.008
All values are medians with interquartile ranges. ‘Control’ is healthy control
group and ‘Pancreatitis’ is chronic pancreatitis group. ‘ePDT’ is electric pain
detection threshold, ‘ePTT’ is electric pain tolerance threshold, ‘pPDT’ is
pressure pain detection threshold, ‘pPPT’ is pressure pain tolerance threshold
and ‘CPM’ is conditioned pain modulation.
doi:10.1371/journal.pone.0042096.t002
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experimental pain model in healthy volunteers showed a reduction
of hyperalgesia and central sensitization after gabapentin treat-
ment. [31,32] Only two studies, one with S-ketamine in chronic
pancreatitis and one with pregabalin in irritable bowel syndrome,
showed comparable reductions of hyperalgesia in patients treated
with medication active in the central nervous system. [12,17] To
Table 3. Sum of pain thresholds for pregabalin vs. placebo before and after treatment.
Before After
Pregabalin Placebo Pregabalin Placebo
SUM ePDT (mA) 33.4 (23.6–43.5) 23.4 (18.9–33.8) 37.3 (27.9–51.6) N 26.1 (17.2–39.7)
SUM ePTT (mA) 53.4 (39.2–67.1) 41.7 (32.6–51.6) 52.3 (38.9–73.9) 44.0 (34.9–55.2)
SUM pPDT (kPa) 1936 (1063–2574) 1759 (902–2449) 1817 (1109–3312) 1817 (844–2585)
SUM pPTT (kPa) 2677 (2043–3136) 2720 (2307–3230) 2798 (2355–3945) 2853 (2131–3264)
All values are medians with interquartile ranges. N = Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo
group.
doi:10.1371/journal.pone.0042096.t003
Table 4. Conditioned pain modulation and pain thresholds for pregabalin vs. placebo before and after study treatment.
Before After
Pregabalin Placebo Pregabalin Placebo
ePDT (mA)
- C5 3.9 (2.5–5.1) 3.5 (2.4–6.0) 4.5 (3.4–5.6) 3.1 (2.1–6.0)
- T4 5.0 (3.0–7.0) 3.5 (2.7–6.3) 6.2 (4.2–8.5) N 3.9 (3.3–7.6)
- T10 5.8 (4.3–8.1) 3.7 (3.0–7.7) 6.5 (4.7–9.2) 4.9 (3.2–7.9)
- L1 4.8 (3.6–6.4) 4.3 (3.1–5.9) 6.6 (4.4–8.9) 4.7 (2.7–8.4)
- L4 5.7 (4.0–8.5) 4.1 (3.2–6.5) 5.8 (4.1–9.1) N 4.4 (3.2–6.6)
- T10 BACK 5.9 (3.8–7.2) 4.8 (3.8–6.9) 5.8 (4.3–10.3) N 4.3 (2.8–7.8)
ePTT (mA)
- C5 6.9 (5.4–10.7) 5.4 (4.1–9.9) 9.6 (5.4–14.4) N 6.3 (5.0–10.7)
- T4 8.9 (5.6–13.0) 7.6 (5.1–10.7) 10.9 (7.5–16.2) 8.6 (5.6–11.6)
- T10 10.6 (6.1–12.7) 7.3 (3.7–10.7) 8.8 (6.1–15.1) 7.9 (5.6–12.6)
- L1 9.5 (6.5–13.5) 7.2 (5.2–11.1) 9.5 (7.0–14.8) N 7.1 (5.8–12.9)
- L4 9.9 (6.7–13.3) 7.4 (5.1–10.0) 9.1 (6.6–14.9) 7.2 (5.7–10.9)
- T10 BACK 11.7 (6.5–16.3) 9.3 (6.4–12.6) 9.1 (6.6–14.9) 8.9 (6.9–12.5)
pPDT (kPa)
- C5 263 (142–334) 232 (106–380) 228 (130–321) 245 (115–398)
- T4 281 (195–392) 289 (139–409) 277 (169–421) 268 (147–359)
- T10 166 (97–302) 154 (85–264) 129 (65–328) 157 (61–306)
- L1 376 (207–511) 340 (197–571) 292 (207–566) 424 (168–528)
- L4 406 (235–601) 396 (176–613) 447 (177–689) 332 (204–641)
- T10 BACK 378 (211–474) 276 (162–522) 332 (132–549) 313 (161–480)
pPTT (kPa)
- C5 421 (313–523) 378 (309–563) 451 (310–614) 459 (358–599)
- T4 481 (307–555) 422 (335–528) 431 (352–691) 371 (284–530)
- T10 246 (165–493) 257 (176–402) 280 (173–570) 236 (156–432)
- L1 578 (454–675) 548 (407–706) 551 (437–716) 581 (479–649)
- L4 608 (530–776) 614 (437–776) 733 (526–933) 700 (508–866)
- T10 BACK 574 (403–699) 561 (476–731) 612 (397–838) 537 (395–635)
CPM response (%) 0.9 (0.0–22.0) 8.9 (0.0–23.8) 0.0 (0.0–22.4) 0.0 (24.0–19.8)
All values are medians with interquartile ranges. N = Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo
group.
doi:10.1371/journal.pone.0042096.t004
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date a more prolonged reduction of somatic hyperalgesia and thus
central sensitization has not been demonstrated in chronic pain
patients in relation to pregabalin treatment.
In this study we failed to show a significant difference between
groups regarding our primary outcome measure (change in sum of
thresholds). The significant result regarding secondary outcome
measure (change in individual dermatomal thresholds) suggests a
moderate effect on spreading hyperalgesia. Interestingly, anti-
hyperalgesic treatment with pregabalin resulted in a greater
increase of electric pain thresholds than of pressure pain thresholds
after three weeks treatment. A possible explanation is that
pregabalin is initially more effective in reducing skin sensitization,
as reflected by electric thresholds, as compared to deep tissue
sensitization, as reflected by pressure thresholds. [32,33] If this
were true, one might expect greater decreases in deep tissue
sensitivity with longer treatment periods in future studies.
In this study no significant improvement in conditioned pain
modulation (CPM) could be found, suggesting that the main effect
of pregabalin is to directly target central sensitization reflected by
hyperalgesia, rather than the pro/anti-nociceptive balance of
endogenous modulation. We did, however, demonstrate that
before treatment, pancreatitis patients showed less inhibitory pain
modulation than healthy controls in accordance with other studies.
[9] However, it should be noted that CPM results exhibited
considerable variability and are influenced by multiple factors.
More research is clearly needed to define the relations between
Table 5. Change and percentage change in conditioned pain modulation and pain thresholds for pregabalin vs. placebo after
study treatment.
Pregabalin Placebo
Change Percentage change (%) Change Percentage change (%)
ePDT (mA)
- C5 0.8 (0.2–1.9) N 24 (5–55) 20.1 (20.9–0.5) 2 (225–16)
- T4 1.5 (20.7–3.0) 39 (213–83) 0.7 (21.1–1.5) 17 (216–49)
- T10 0.8 (20.7–3.1) 12 (211–52) 0.4 (20.7–1.4) 8 (29–40)
- L1 1.2 (20.2–3.8) 25 (26–71) 0.3 (20.5–2.3) 11 (211–51)
- L4 0.9 (20.8–2.3) 14 (216–46) 0.7 (20.9–1.7) 18 (222–37)
- T10 BACK 0.6 (21.2–4.3) 16 (222–75) 20.6 (21.4–1.3) 214 (229–14)
ePTT (mA)
- C5 2.0 (20.1–3.7) N 25 (21–64) 0.7 (22.4–1.9) 12 (227–40)
- T4 2.6 (20.6–5.1) 41 (25–60) 1.5 (20.9–2.9) 15 (212–46)
- T10 1.0 (20.8–2.4) 10 (210–27) 0.8 (21.2–2.4) 17 (29–53)
- L1 1.9 (20.8–4.9) N 29 (27–59) 20.2 (22.3–2.1) 23 (228–38)
- L4 1.5 (22.0–5.2) 22 (220–53) 20.3 (21.2–3.0) 0 (214–83)
- T10 BACK 1.1 (21.9–4.8) 10 (220–57) 20.5 (22.8–2.7) 25 (221–36)
pPDT (kPa)
- C5 12 (279–89) 7 (239–34) 213 (251–50) 27 (219–31)
- T4 9 (291–72) 4 (234–26) 23 (289–45) 21 (229–13)
- T10 13 (231–77) 6 (231–53) 21 (251–26) 0 (224–15)
- L1 63 (2137–117) 18 (239–53) 12 (299–135) 9 (219–40)
- L4 80 (2129–176) 18 (230–37) 0 (250–88) 0 (213–23)
- T10 BACK 41 (263–89) 9 (27–31) 34 (273–90) 9 (224–24)
pPTT (kPa)
- C5 19 (265–152) 3 (217–40) 17 (232–103) 5 (29–31)
- T4 83 (224–169) N 18 (27–43) 248 (2108–43) 213 (221–12)
- T10 10 (256–111) 5 (215–53) 20 (2103–56) 7 (234–23)
- L1 27 (282–136) 21 (216–32) 69 (2149–144) 16 (219–28)
- L4 17 (2253–278) 6 (230–53) 75 (15–225) 12 (3–33)
- T10 BACK 41 (274–194) 5 (215–40) 14 (2165–81) 3 (227–21)
SUM ePDT 6.0 (21.2–15.0) 19 (26–62) 2.3 (21.9–5.8) 9 (28–19)
SUM ePTT 7.6 (27.1–13.5) 13 (214–25) 2.7 (27.1–10.9) 7 (215–28)
SUM pPDT 311 (2155–526) 16 (29–39) 131 (2330–329) 11 (214–20)
SUM pPTT 226 (2265–593) 10 (214–20) 193 (2192–380) 8 (26–17)
CPM response (%) 1 (24–18) 218 (2100–134) 22 (223–6) 2100 (2136–16)
All values are medians with interquartile ranges. N = Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo
group.
doi:10.1371/journal.pone.0042096.t005
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CPM, disease-related changes in central pain processing, and pain
treatment effects. [9,34].
A limitation of this study is the relatively small size of the
chronic pancreatitis group. A larger sample of chronic pancreatitis
patients would appear necessary to provide more detailed and
significant evidence of the relation between pregabalin treatment,
changes in pain scores and changes in hyperalgesia. While we did
find parallel, separate reductions in pain scores and pain sensitivity
in our patient collective, the study was not adequately powered to
formally study – or prove – correlations between clinical pain
reduction and reduction in hyperalgesia. Definitive proof of such a
relationship awaits future larger and longer-lasting trials. It should
be noted that most chronic pancreatitis studies are small due to the
difficulties in recruiting large groups of uniform chronic pancre-
atitis patients. Better and larger national and international
collaborations are necessary to permit larger and longer popula-
tion based trials in chronic pancreatitis.
In this study an intention to treat analysis was performed
conform the international standard for randomized clinical trials.
It can be argued that for the mechanistic endpoints an analysis
including only patients fully compliant with the study protocol
should be performed (per protocol analysis). We therefore also
performed a per protocol analysis, but we did not present these
data in this manuscript, because there were no major differences
compared to the intention to treat analysis. [14] We checked
variability between the study groups and found that standard
deviations were comparable between both the groups at the
different times. The presence of diabetes mellitus, alcohol
consumption and the wide range of morphine dosages might
have influenced our results. Certainly some patients might have
shown diabetic polyneuropathy or morphine induced hyperalge-
sia, which could have biased our results. However during the
physical examination of trial participants no peripheral sensory or
motor disturbances were detected and all baseline characteristics
were equally distributed between both treatment groups. There
was a significant difference in age between the healthy controls
and the chronic pancreatitis patients. The importance of this
difference is difficult to assess. Some studies described an increase
of pain thresholds during aging [35], others showed no effect [36]
and some showed a decrease in thresholds during aging [37].
Another limitation of the study is the absence of a long-term
follow-up. We only measured effects after a relatively short
treatment period of three weeks. At this time, modest reductions in
distant skin hyperalgesia were already noticeable and significant,
albeit without return to normal values (i.e. as in healthy
volunteers). This reduction in hyperalgesia occurred in a patient
population with a long history of chronic pancreatitis, generally
regarded as being particularly difficult to manage.
In conclusion our study provides first evidence that pregabalin
modestly reduces the spreading hyperalgesia as manifestation of
central sensitization associated with chronic pancreatitis pain. This
effect was evident after three weeks of pregabalin treatment and
was most evident for electric skin pain thresholds. However more
research is needed to predict the long-term effects and define
effective dosage schemes for pregabalin use in different stages of
chronic pancreatitis.
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